Chaomin Li

USPTO Granted Patents = 7 (Patent Applications = 2)

CIPO Patents = 1

EPO Patents = 6 (Patent Applications = 5)

Average Co-Inventor Count = 12.3

ph-index = 1

Forward Citations = 23(Granted Patents)

Company Filing History:

7 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2013-2022

Loading Chart...

7 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11230547 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2022-01-25),

2. 11179389 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2021-11-23),

3. 10100064 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2018-10-16),

4. 9540377 - 2,6,7,8 substituted purines as HDM2 inhibitors (2017-01-10),

5. 8759579 - Cyclobutyl sulfones as notch sparing gamma secretase inhibitors (2014-06-24),

6. 8575150 - Triazole derivatives for treatment of Alzheimer's disease (2013-11-05),

7. 8551984 - Aminopyrimidines as SYK inhibitors (2013-10-08),

Title: Chaomin Li: A Prolific Inventor in Boston

Introduction:

Chaomin Li, a talented inventor based in Boston, Massachusetts, has made significant contributions to the field of pharmaceuticals with a total of 7 patents to his name. His groundbreaking work has been focused on developing compounds that target human phosphatidylinositol 3-kinase delta (PI3K-delta) for the treatment of various diseases such as inflammation, asthma, COPD, and cancer.

Latest Patents:

Chaomin Li's latest patents include novel purine inhibitors of human phosphatidylinositol 3-kinase delta. These compounds, outlined in formulas Ia, Ib, and I, serve as potent PI3K-delta inhibitors with promising implications for combating PI3K-delta-mediated ailments.

Career Highlights:

Throughout his career, Chaomin Li has been associated with reputable pharmaceutical companies such as Merck Sharp & Dohme Corporation and Merck Canada Inc.. His expertise and innovative approach have played a pivotal role in advancing the development of therapeutic agents targeting PI3K-delta.

Collaborations:

In his quest for scientific excellence, Chaomin Li has collaborated closely with esteemed colleagues such as Hua Zhou and Matthew Christopher. Together, they have fostered a dynamic research environment, leading to the successful implementation of novel drug candidates.

Conclusion:

Chaomin Li's relentless dedication to scientific innovation and his remarkable contributions to the pharmaceutical industry underscore his status as a pioneering inventor. His patents and collaborations stand as a testament to his invaluable impact on the field of medicine, offering new hope for patients battling PI3K-delta-related conditions.

This text is generated by artificial intelligence and may not be accurate.